SCLERODERMA

This early-phase trial tests a new drug called PRO-203, given as a single shot under the skin. First, healthy volunteers will check safety; then, people with systemic sclerosis (a rare autoimmune disease that hardens skin and organs) will receive the drug. The main goal is to see…

This phase 2 trial tests a therapy called AlloNK, made from donor cord blood immune cells, combined with the drug rituximab. It aims to see if this combination is safe and can help people with severe forms of rheumatoid arthritis, Sjögren's disease, myositis, or scleroderma that …

This early-stage study tests a new drug called SAR448501 (DR-0201) in 62 adults with lupus or rheumatoid arthritis. The drug is a bispecific antibody designed to target the immune system. The main goal is to check safety and find the right dose, not yet to prove it works. Partici…

This early-stage study tests a new treatment called CABA-201 for people with systemic sclerosis (scleroderma), a disease that causes hardening of the skin and can damage organs. The treatment uses a patient's own immune cells, modified to target and destroy faulty B cells that dr…

This early-stage study tests a new therapy, HN2301, in 30 adults with lupus, scleroderma, or rheumatoid arthritis. The main goal is to check safety and find the right dose. Researchers will also look for early signs that the treatment helps control the disease by measuring immune…

This early study is testing an experimental therapy called EVM18001 in 12 people with active, hard-to-treat lupus, myasthenia gravis, or scleroderma. The main goal is to see if it is safe and to find the right dose. Researchers will also look at how the body processes the therapy…

This Phase 2 trial tests a drug called tibulizumab in 80 adults with systemic sclerosis, a disease that causes skin thickening and can damage organs. Participants first receive either the drug or a placebo for 24 weeks, then everyone who continues gets the drug for another 28 wee…

This study tests whether new investigational drugs can improve lung function in people with scleroderma-related lung scarring. About 400 adults with this condition will receive either the study drug or a placebo for 52 weeks. The main goal is to see if the drug helps preserve or …

This phase 2 trial tests whether sildenafil, a drug used for pulmonary hypertension, can help people with scleroderma who have mildly elevated lung pressures. Thirty participants will receive either sildenafil or a placebo for 4 months. The main goal is to see if the drug improve…

This study is testing a structured exercise program called BETY, which focuses on the whole person (body, mind, and social factors), in 48 children and adults with scleroderma. Participants will either do the BETY program for 3 months or follow a home exercise routine. The goal i…

This study aims to uncover genetic changes that cause autoimmune diseases in people native to Peru. Researchers will collect blood, urine, and stool samples from 300 participants, including patients with conditions like lupus and rheumatoid arthritis, their family members, and he…

This study looks at why people with interstitial lung disease (ILD) often feel breathless and have trouble exercising. Researchers think leg muscle problems might be a cause. They will measure leg muscle strength and structure in 40 ILD patients and test how extra oxygen affects …

This study is creating a large database of information from 10,000 people with esophagus problems like GERD, achalasia, and other motility disorders. Researchers will collect data from standard tests to better understand these conditions. The goal is to improve diagnosis and trea…

This study aims to collect blood samples and medical data from 3000 people with autoimmune diseases like lupus, scleroderma, and myositis. Researchers will use these samples to find new biomarkers and better understand these conditions. The goal is to help develop new treatments …

This study is building a large registry and biorepository of 5,000 adults with various rheumatic diseases like rheumatoid arthritis, lupus, and scleroderma. Researchers at Yale University will collect medical data and biological samples over time to better understand these condit…

This study looks at skin cells called fibroblasts from people with scleroderma and healthy volunteers. Researchers want to find which genes are turned on or off in these cells, especially those linked to aging and inflammation. The goal is to better understand what causes the dis…

This registry enrolls pregnant women or those planning pregnancy who have autoimmune diseases like lupus or rheumatoid arthritis. Researchers at Duke University will track health data to find ways to improve outcomes for mothers and babies. The goal is to better understand risk f…

This registry is collecting medical information and biological samples from 300 adults with scleroderma at a single hospital. The goal is to better understand the disease's features, genetics, and progression. While this study does not test any treatment, the data gathered could …

This study collects tissue and blood samples from 300 people with autoimmune diseases like Crohn's, multiple sclerosis, and celiac disease. Researchers aim to identify the specific targets of immune cells (T cells) that cause inflammation. The goal is to discover new targets for …

This study looks at how biological, psychological, and social factors affect physical performance in people with scleroderma. Researchers will test 50 children and adults using simple tasks like walking, stair climbing, and standing up from a chair. The goal is to find better way…

This study looks at how scleroderma affects chewing and swallowing in both children and adults. Researchers will use questionnaires and physical tests to measure these functions and understand the overall well-being of participants. The goal is to find better tools for assessing …

This study follows 500 adults with systemic sclerosis (scleroderma) for up to 5 years. Researchers will collect blood samples, and in some volunteers, skin or lung samples, to track how the disease changes over time. The goal is to better understand the natural course of this rar…